Taken together, the presence of PIK3CA mutations in our samples cohort suggests that a substantial number of NPC patients can likely benefit from therapies that target the PI3K/Akt/mTOR pathway. The gene discussed is MTOR; the disease is nasopharyngeal carcinoma.